The Current Ratio as of September 2024 (TTM) for Aeglea BioTherapeutics, Inc. (AGLE) is 4.59

According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.59. This represents a change of 37.19% compared to the average of 3.35 of the last 4 quarters.

Aeglea BioTherapeutics, Inc. (AGLE) Historical Current Ratio (quarterly & annually)

How has AGLE Current Ratio performed in the past?

The mean historical Current Ratio of Aeglea BioTherapeutics, Inc. over the last ten years is 7.73. The current 4.59 Current Ratio has changed 5.83% with respect to the historical average. Over the past ten years (40 quarters), AGLE's Current Ratio was at its highest in in the March 2015 quarter at 37.12. The Current Ratio was at its lowest in in the March 2014 quarter at 0.

Aeglea BioTherapeutics, Inc. (AGLE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aeglea BioTherapeutics, Inc. (AGLE) Average Current Ratio

How has AGLE Current Ratio performed in the past?

The current Current Ratio of Aeglea BioTherapeutics, Inc. (AGLE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Aeglea BioTherapeutics, Inc. (AGLE) Current Ratio vs. Peers

How is AGLE’s Current Ratio compared to its peers?

Aeglea BioTherapeutics, Inc.’s Current Ratio is less than Edgewise Therapeutics, Inc. (30.24), less than Ikena Oncology, Inc. (18.22), less than Design Therapeutics, Inc. (41.42), greater than Xilio Therapeutics, Inc. (2.02), less than Eliem Therapeutics, Inc. (60.41), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than Landos Biopharma, Inc. (4.43), greater than Apexigen, Inc. (0.82), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Angion Biomedica Corp. (1.74), less than SAB Biotherapeutics, Inc. (5.24), less than Senti Biosciences, Inc. (4.89), greater than Cingulate Inc. (1.20), greater than Bellicum Pharmaceuticals, Inc. (3.04), greater than Hillstream BioPharma, Inc. (2.25), less than Neoleukin Therapeutics, Inc. (15.33), greater than CytomX Therapeutics, Inc. (1.00), greater than Assembly Biosciences, Inc. (2.74), less than Instil Bio, Inc. (15.06), less than Nuvation Bio Inc. (11.49), less than Applied Molecular Transport Inc. (4.99), greater than Catalyst Biosciences, Inc. (0), less than Aileron Therapeutics, Inc. (4.69), greater than Bio-Path Holdings, Inc. (1.67), greater than Benitec Biopharma Inc. (4.18),

Build a custom stock screener for Aeglea BioTherapeutics, Inc. (AGLE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aeglea BioTherapeutics, Inc. (AGLE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.